Curious to know what's happening on the US markets one hour before the close of the markets on Friday? Join us as we explore the top gainers and losers in today's session.
Shares of medical device company Globus Medical (NYSE:GMED)
jumped 32.7% in the afternoon session after the company reported third-quarter results that significantly beat analyst estimates and raised its full-year guidance.
Medical device company Globus Medical (NYSE:GMED) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 22.9% year on year to $769 million. The company’s full-year revenue guidance of $2.88 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $1.18 per share was 53.4% above analysts’ consensus estimates.
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Globus Medical's Q3 2025 earnings crushed estimates, with EPS of $1.18 beating by 47%. The stock surged over 22% as the company also raised its full-year profit guidance.
Medical device company Globus Medical (NYSE:GMED) announced better-than-expected revenue in Q3 CY2025, with sales up 22.9% year on year to $769 million. The company’s full-year revenue guidance of $2.88 billion at the midpoint came in 0.8% above analysts’ estimates. Its non-GAAP profit of $1.18 per share was 53.4% above analysts’ consensus estimates.
Growth boosts valuation multiples, but it doesn’t always last forever.
Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who lost money in tech stocks during 2022.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Globus Medical (NYSE:GMED) and its peers.
Businesses with strong free cash flow tend to be more adaptable and resilient.
Some of these companies shine bright by using their cash wisely to strengthen their market positions.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
Globus Medical’s stock price has taken a beating over the past six months, shedding 21.5% of its value and falling to $57.60 per share. This may have investors wondering how to approach the situation.
